17 results about "Tumour therapy" patented technology

Provided is a method of oncolytic virus therapy for a tumour based on using neutrophil count as a predictor of the efficacy of oncolytic virus therapy for the tumour, comprising: determining the neutrophil count level in the blood of a tumour patient prior to tumour treatment; and, when the neutrophil count level in the blood of the tumour patient is below a cut-off value, administering an oncolytic virus to the tumour patient for treatment, wherein the cut-off value is any value from 2×109 to 5.5×109 / L.

A pharmaceutical combination product including:a liposomal formulation consisting of one or more liposomes each encapsulating a bacterial lipopolysaccharide (LPS) as a single active ingredient; andat least one anti-tumor compound chosen from the group consisting of: a therapeutic antibody, a chemotherapy agent, and an immunotherapy agent.Methods for treating a tumor comprising administering to a patient having said tumor an effective amount of said pharmaceutical combination product.

Alternating electric fields (e.g., TTFields) may be applied to the body of a subject using one or more electrode assemblies including a sheet of anisotropic material, at least one conductive material layer disposed on a front surface of the sheet of anisotropic material, and an electrode element disposed behind the sheet of anisotropic material. The electrode element has a front surface disposed in electrical contact with a rear surface of the sheet of anisotropic material. The sheet of anisotropic material spreads both heat and current in a direction parallel to the front surface of the sheet, eliminating or at least minimizing hot spots on the electrode assembly. This in turn allows for increased current flow without exceeding a temperature safety threshold (e.g., 41°C).

This invention provides a benzothiadiazine compound that inhibits histone deacetylases, its preparation method, and its applications. The general structural formula is shown in Formula (I), or an isomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug thereof. The benzothiadiazine compound of this invention has a novel structure and, as an inhibitor of histone deacetylases HDAC6 and HDAC1, can effectively inhibit the proliferation of K562 (human chronic myeloid leukemia cells) and NCI-H929 (human myeloma cells). It exhibits low cytotoxicity to normal cells and low potential cardiac risk, and holds promise as a highly effective and low-toxicity antitumor therapeutic agent.

The invention provides hsatsr016846 for a gastric cancer treatment target and / or a diagnostic biomarker and application of the hsatsr016846, and belongs to the technical field of biology. The hsatsr016846 for the gastric cancer treatment target and / or the diagnostic biomarker is a tRNA (transfer ribonucleic acid) derivative fragment, and the nucleotide sequence is as shown in SEQ ID NO: 1. High expression of the hsatsr016846 significantly inhibits migration and invasion of gastric cancer cells, the expression level of the hsatsr016846 is significantly different in gastric cancer tissue and gastric cancer para-tissue, and the low expression state of the hsatsr016846 is more likely to appear in advanced gastric cancer (TNM III / IV) patients. Therefore, the hsatsr016846 can be used as a tumor treatment target and a diagnostic biomarker to be applied to tumor treatment, tumor diagnosis and tumor prognosis evaluation.

The invention relates to the technical field of tumor treatment, in particular to a VEGFR-2 / BRD4 double-target inhibitor and application thereof. The structural general formula of the VEGFR-2 / BRD4 double-target inhibitor is as shown in a formula I in the specification. The tetrahydropteridine compound containing the aryl amide or aryl urea structure, disclosed by the invention, has relatively strong inhibitory activity on VEGFR-2 / BRD4 activity; according to the present invention, the VEGFR-2 / BRD4 double-target inhibitor has good anti-proliferative activity on tumor cells, the compound I-5 shows the optimal activity, and the activity is far superior to the positive control Sorafenib, ReGrafenib and JQ-1, the effect of the ReGrafenib and the effect of the combination of the Sorafenib and the JQ-1 respectively, and the target treatment drug for leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like can be prepared, and the compound I-5 can be used for the preparation of the target treatment drug for treating leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like.

The present invention provides a compound, preferably a peptide, having the following characteristics:a) consisting of 9 amino acids in a linear arrangement;b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group;c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionallyd) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionallye) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues;for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents. Also provided are the peptidic compounds as defined above for use in the destabilisation of a mitochondrial membrane, and a peptidic compound as defined above and an immunotherapeutic agent as a combined preparation for separate, simultaneous or sequential use in treating tumours.

The present application relates to the field of tumor treatment, and particularly relates to a combination of a selective VEGFR3 inhibitor and an anti-PD-L1 antibody and application thereof in lung cancer treatment.

The present invention relates to a pharmaceutical combination product comprising:a liposomal formulation exclusively containing a LPS; andat least one cytotoxic compound.It also relates to its use as an anti-tumour therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mouse T lymphocyte-derived extracellular vesicles in treatment or relief of colorectal cancer. The extracellular vesicles are derived from cytotoxic T lymphocyte line 2 (Cytotoxic T Lympholyte Line 2, CTLL2), and the CTLL2-derived extracellular vesicles extracted by using an exosome extraction kit after a differential centrifugation method can effectively influence the biological functions of colorectal cancer cell lines, inhibit the growth of colorectal cancer tumors and reduce the death rate of colorectal cancer model mice. In addition, the extracellular vesicles have no injury effect on important organs such as heart, liver, spleen, lung, kidney and the like of a mouse; results show that the extracellular vesicles derived from mouse T lymphocytes have a good effect in the aspect of colorectal cancer treatment and show application potential in the field of tumor treatment.